Clinical Trial Details


Research Study Summary

New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS) who have had a documented relapse in the last year


This is a 12 month study to compare the safety and efficacy of 2 doses of Fingolimod (0.25mg and 0.5mg) every day vs Copaxone 20mg SC every day for patients with RRMS.

Patient Inclusion Criteria:

  • 18-65
  • 1 documented relapse in the last year
  • NO monoclonal antibodies within 6 months prior to start of study medication
  • NO varicella zoster
  • Heartrate must be greater than 45/bpm
  • NO uncontrolled diabetes with HbA1c >7%
  • Cannot have positive Hepatitis A, B, C and E

To Learn more

CW ID: 182097
Date Last Changed: July 18, 2013

Clinical Trial Snapshot

Both Male and Female
18 to 65 Years
Overall Status
12 Months
Facility Type


Alpine Clinical Research Center
1000 Alpine Avenue , Suite 200
Boulder, CO 80304
Phone: 303-443-7229

View Map

Research Center Information:

Alpine Clinical Research Center

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.